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1. Introduction 
Type 2 diabetes (T2DM), also known as non-insulin-dependent diabetes mellitus (NIDDM), 
manifests with an inability to adequately regulate blood-glucose levels. T2DM may be 
characterized by a defect in insulin secretion or by insulin resistance, namely those that 
suffer from T2DM have too little insulin or cannot use insulin effectively. Insulin resistance 
which refers to the inability of body tissues to respond properly to endogenous insulin 
develops because of multiple factors, including genetics, obesity, increasing age, and having 
high blood sugar over long periods of time[1]. 
Current therapies for diabetes mellitus include: glucose-lowering effectors, such as 
metformin which reduces glucose production from the liver; insulin; insulin secretagogues, 
such as sulphonylureas, which increase insulin production from pancreatic β-cells; 
activators of the peroxisome proliferator-activated receptor-γ (PPAR-γ), such as the 
thiazolidinediones, which enhance insulin action; and α-glucosidase inhibitors which 
interfere with gut glucose production. There are, however, deficiencies associated with 
currently available treatments, including hypoglycemicepisodes, weight gain, loss in 
responsiveness to therapy over time, gastrointestinal problems, and edema[2]. Glucagon-
like peptide 1 (GLP-1) analogs and dipeptidyl peptidase 4 (DPP-4) inhibitors are also widely 
used in clinical therapy for T2DM. GLP-1 analogs, which require parenteral administration, 
appear not to be associated with hypoglycemia but cause a relatively high frequency of 
gastrointestinal side effects[3]. Small molecule DPP-4 inhibitors enhance glucose-dependent 
insulin release by inhibiting the degradation of endogenous GLP-1[4]. Several nonpeptide, 
except DPP-4 inhibitors, binding G protein-coupled receptors (GPCRs) have been 
deorphanized recently and are currently being evaluated as candidate GLP-1 secretagogues 
for T2DM[5, 6]. Among these, the G protein-coupled receptor 119 (GPR119) has received 
considerable attention from the pharmaceutical industry in recent years. GPR119 may 
 
Diabetes Mellitus – Insights and Perspectives 60 
present an attractive drug target for treating T2DM, and its agonists may therefore represent 
potential new insulin secretagogues free of the risk of causing hypoglycemia. 
GPR119 has been described as a class A (rhodopsin-type) orphan GPCR without close 
primary sequence relative in the human genome[7]. The activation of GPR119 increases the 
intracellular accumulation of cAMP, leading to enhanced glucose-dependent insulin 
secretion from pancreatic β-cells and increased release of the gut peptides GLP-1 (glucagon-
like peptide 1), GIP (glucose-dependent insulinotropic peptide) and PYY (polypeptide 
YY)[8]. Preclinical and clinical studies with GPR119 agonists in type 2 diabetes support that 
GPR119 agonists have been proposed as a novel therapeutic strategy for diabetes. These 
investigations indicate that orally available, potent, selective, synthetic GPR119 agonists: a) 
lower blood glucose without hypoglycemia; b) slow diabetes progression; and c) reduce 
food intake and body weight. This review provides an overview of the recent progress made 
in the discovery of orally active GPR119 agonists[9], and outlines the current clinical trial 
landscape and paints a detailed illustration of the key structural information realized from 
GPR119 agonist campaigns. 
2. GPR119: A historical perspective 
2.1. Discovery and characteristics of GPR119 
After the discovery of GPR119 in 1999 using data afforded by the Human Genome Project, it 
was subsequently described in the peer-reviewed literature as a Class A receptor with no 
close relatives. Independently, this receptor has been studied and described in the literature 
under various synonyms, including SNORF25 [10, 11], RUP3 [12], GPCR2 [13] , 19AJ [14] , 
OSGPR116 [15], MGC119957, HGPCR2 and glucose-dependent insulinotropic receptor 
(GDIR) [9]. This potentially confusing nomenclature has now been largely rationalized in 
favor of the designation “GPR119”. 
The human receptor is encoded by a single exon with introns located on the short arm of X- 
chromosome (Xp26.1) (Figure 1). GPR119 homologs have been identified in several 
vertebrate species, including the rat, mice, hamster, chimpanzee, rhesus monkey, cattle and 
dog[14]. Fredriksson et al. (2003) report the rat isoform of GPR119 (accession number 
AY288429) as being 133 amino acids longer than the mouse and human receptors (468 vs. 
335 amino acids)[16]. In contrast, Bonini et al. (accession number AR240217) and Ohishi et 
al. give identical sequences for the rat receptor, which are 335 amino acids in length and 
have 96% amino-acid identity with mouse GPR119[10, 11, 17].  
2.2. GPR119 Receptor Expression 
Using methods to detect receptor GPR119 mRNA, it has been proposed that, in human 
tissues, the pancreas and foetal liver have been consistently identified as major sites of 
GPR119 mRNA expression, with high expression also being noted in the gastrointestinal 
tract in several studies, while, in rodents, mRNA was detected in most of the tissues 
examined [9-11] , with the pancreas [12, 18] and gastrointestinal tract, in particular the colon 
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and small intestine, again appearing as major sites of expression. GPR119 expression has 
also been described in certain regions of the rat brain. 
 
Figure 1. Schematic summary of Human GPR119 membrane topology model. Clusters of serine (S) 
and threonine (T) residues are highlighted in blue orange circles in the third intracellular loop and the 
C-terminus domain, and could represent potential sites of phosphorylation. 
In situ reveals that pancreatic β cells are the main site of GPR119 expression in pancreatic 
islets[19]. High expression levels in pancreatic β cell lines NIT-1, MIN6 and RIN5 supports 
this observation[18, 20, 21]. Consistent with its expression in gut tissues, GPR119 mRNA 
was strongly expressed in several rodent GLP-1 secreting L-cell lines-including STC-1, FRIC, 
Hnci-h716 and GLUTag line[21, 22]. GPR119 mRNA has also been found in glucose-
dependent insulinotropic peptide (GIP)-producing murine intestinal K cells[23]. 
2.3. GPR119 signaling and de-orphanization 
High-level expression of GPR119 in transfected HEK293 cells led to an increase in 
intracellular cAMP levels via activation of adenylate cyclase [10, 11, 19], indicating that this 
receptor couples efficiently to Gαs. In support of these data, potential endogenous ligands 
and synthetic small molecule agonists of GPR119 have been shown to increase cAMP levels 
(Figure 2).  
Lysophosphatidylcholine (LPC, Figure 3, 1) was the first proposed endogenous ligand for 
GPR119, based on its ability to stimulate glucose-dependent insulin release and increase cAMP 
in GPR119-transfected cells. Overton et al. have reported that the fatty-acid amide 
oleoylethanolamide (OEA, Figure 3, 2) promotes a concentration-dependent increase in cAMP 
levels in stably transfected and endogenous GPR119-expressing cell lines with potency that 
was greater than LPC[24]. The identification of OEA as a potential endogenous ligand for 
GPR119 was of particular interest, since this compound has been reported to produce a 
number of pharmacological effects in rodent studies[25], including: a) reducing food intake 
and body weight gain through interacting with the nuclear receptor peroxisome proliferator-
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activated receptor α (PPAR-α)[16, 26]; b) increasing fatty acid uptake by adipocytes and 
enterocytes through increased fatty acid translocase expression[27]; and c) altering feeding 
behaviour and motor activity through activation of an ion channel, the transient receptor 
potential  channel, subfamily V, member 1 (TRPV1)[28]. The endovanilloid compounds N-
oleoyl dopamine (OLDA, Figure 3, 3) and olvanil have recently been described as GPR119 
agonists with in vitro potencies similar to that of OEA. Moreover, in vivo studies 
demonstrated that oral administration of OLDA (100 mg/kg) increased GIP release and 
improved oral glucose tolerance in mice; these effects were absent or attenuated in GPR119 
null mice. These fatty acid amides, OEA and OLDA, represent the best candidates for 
endogenous ligands, although they are less potent and selective than the natural ligands 
identified for many other GPCRs. Nonetheless, this work raises the possibility that other lipid 
amides may play a physiological role via GPR119 signaling[23, 25]. 
 
Figure 2. Schematic diagram illustrating the possible actions of GPR119 agonists[23]. GPR119 is 
expressed on certain enteroendocrine cells (L and K cells) in the small intestine and by β-cells within the 
islets of Langerhans of the pancreas. In all three cell types, ligation of GPR119 by an agonist leads to the 
activation of adenylate cyclase and a rise in cAMP. This triggers the release of glucagon-like peptide 1 
(GLP-1), and glucose-dependent isulinotropic peptide (GIP) or insulin from L, K and β-cells, 
respectively. Addtitionally, GLP-1 and GIP can both interact with their cognate receptors on the β-cell 
to elicit insulin secretion. Thus, GPR119 agonists lead to a rise in insulin release by both direct 
mechanisms. Since GLP-1 (and probably GIP) also promotes β-cell viability, it is possible that orally 
acting GPR119 agonists may influence both the secretory activity and the viability of β-cells, leading to 
improved glucose homeosetasis in patients with T2DM. 
 
GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment 63 
 
Figure 3. Proposed ligands of GPR119. 
3. GPR119 regulation of insulin and incretin secretion 
3.1. GPR119 regulation of insulin secretion 
Based on the expression profile and coupling properties of GPR119, it stands to reason that 
activation of the receptor in pancreatic β cells might lead to enhanced glucose-dependent 
insulin release. Although the mechanism by which insulin secretion is increase following the 
activation of GPR119 involves a rise in cAMP, Ning et al. have demonstrated that 
potentiation of insulin secretion is also dependent on the closure of ATP-sensitive K+ 
channels and the consequent gating of voltage sensitive calcium channels[29]. The potent, 
selective GPR119 agonist discovered at Arena Pharmaceuticals, Inc., AR231453 (Figure 3, 4), 
significantly increased insulin release in HIT-T15 cells (a hamster insulinoma-derived line 
with robust GPR119 expression) and in rodent islets. By contrast, no effect of this compound 
could be seen in islets isolated from GPR119-deficient mice, confirming that its effects were 
indeed mediated by GPR119[25]. 
3.2. GPR119 regulation of incretin secretion 
GPR119 stimulates the release of GIP, GLP-1 and at least one other L-cell peptide, peptide 
YY (3-36) (PYY)[30]. GPR119 mRNA was found to be expressed at significant levels in 
intestinal sub-regions that produce GIP and GLP-1. Cellular expression studies have 
extended these observations by showing that most GLP-1 producing L cells in the ileum and 
colon also contain GPR119 [30]. This is consistent with data showing high GPR119 
expression in most in vitro L-cell models[30, 31]. GIP, the other major insulinotropic 
hormone of the gut, is produced primarily in the duodenal K cells (Figure 2).  
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In considering the actions of GPR119 agonists as pontential mediators of GLP-1 and GIP 
secretion, and the potential beneficial actions that derive from this, it should not be 
overlooked that the enteroendocrine cells from which these incretins are released, also 
secrete a range of additional products, including GLP-2, oxyntomodulin (OXM), 
cholecystokinin, and PYY from L cells, as well as xenin from K cells. So far, very little 
attention has been paid to these additional intestinal peptides during analysis of GPR119-
mediated responses in vivo, but it is clear that their actions may be important in 
determining of the overall profile of metabolic responses following administration of 
GPR119 agonists. The role of these additional hormonal agents will required to clarify in 
the further study[23]. 
4. GPR119 Agonists: Medicinal chemistry 
4.1. Clinical trial status and future prospects 
It is hardly surprising that, based on the strong biological proof of concept generated using 
the potent, selective agonist molecule 4[19, 30, 32]. In recent years, numerous patents 
describing GPR119 agonists have been disclosed, and several companies have advanced 
GPR119 agonists into the clinic for the treatment of type 2 diabetes (Table 1, Figure 4): 
Ortho-McNeil/Arena (APD-668 and APD-597; both discontinued), Sanofi-Aventis/Metabolex 
(SAR-260093/MBX-2982; Phase 2), Glaxo-SmithKline (GSK-1292263; Phase 2), 
Astellas/Prosidion (PSN-821; Phase 2) and Bristol-Meyers Squibb (Phase 1). The following 
sections provide an overview of the multiple classes of GPR119 agonists, along with the 
available biological data, reported by various pharmaceutical organizations. Each section is 
categorized according to applicant. 
 
 
 
 
 
 
 
 
 
Figure 4. Structures of GPR119 agonists (MBX-2982 [5] and GSK1292263 [6]). 
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Drug Company 
Highest
development 
status 
ClinicalTrials.gov identifier 
SAR-260093 
/MBX-2982 
Sanofi-Aventis 
/Metabolex 
Phase 2 NCT01035879 
GSK-1292263 GlaxoSmithKline Phase 2 
NCT01119846, NCT01218204, 
NCT01128621, NCT00783549, 
NCT01101568 
PSN-821 Astellas/Prosidion Phase 2 NCT01386099 
APD-668 Ortho-McNeil/Arena Discontinued 
APD-597 Ortho-McNeil/Arena Discontinued 
Table 1. GPR119 agonists currently in development. 
4.2. Available structures of GPR119 agonists 
4.2.1. Arena pharmaceuticals 
Arena Pharmaceuticals has been actively pursuing two GPR119 modulators, derived 
from 4 that were both considered for progression into human clinical, studies as 
potential drug candidates after the discovery and validation of this receptor as a viable 
target for the treatment of metabolic disorders. In December 2004, Arena announced a 
collaboration agreement with Ortho-McNeil Pharmaceutical, Inc., under which two 
Arena-discovered GPR119 agonists were selected for preclinical development (Arena 
Pharmaceuticals, Inc., Press Release, December 23, 2004, http://arna.client.shareholder. 
com/releasedetail.cfm?ReleaseID=320778 ). The first compound, APD668 (also known as 
JNJ28630355), displayed high GPR119 potency across various species (hEC50 = 0.47 nM, 
mEC50 = 0.98 nM, rEC50 = 2.51 nM; melanophore dispersion assay) and demonstrated 
good in vivo activity (3–30 mg/kg, p.o.) in rat and mouse oGTT studies. Compared to a 
known DPP-IV inhibitor, APD668 (Figure 5, 7) was found to be more potent at a dose of 
30 mg/kg. In addition to delaying the onset of hyperglycemia, APD668 delayed elevation 
of HbA1c and also decreased the levels of triglycerides and free fatty acids. Furthermore, 
APD668 demonstrated a reduction in food intake (30mg/kg) causing a slight decrease in 
body weight[8, 33]. However, APD668 was a potent inhibitor of CYP2C9 (IC50 = 0.1 μM), 
a hydroxylated metabolite 8 (Figure 5) was shown to accumulate to a much greater 
extent than was expected based on observations in preclinical species that showed such 
accumulation only at very high doses (>300 mg/kg). Though 8 showed only 80–90% of 
the exposure of 7 after 24 h, as a result of its significantly longer half-life (41–50 h) 
compared to 7 this ratio was increased to 4.3- to 5.1-fold after 14 days of dosing. 
Although this metabolite did not have significant activity at the target receptor (either in 
agonist or antagonist assays), the high concentration and long half-life were considered a 
potential liability for the further development of APD668 (Arena Pharmaceuticals, Inc., 
Press Release, January 07, 2008; http://arna.client.shareholder.com/releasedetail.cfm? 
ReleaseID=320208).  
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Figure 5. Early clinical candidates for GPR119 derived from the tool compound AR231453 and the 
structure of the major hydroxylated metabolite of APD668[34]. 
To tackle the CYP2C9 inhibition we elected to focus primarily on our alternative scaffold, as 
exemplified by 9 (Figure 5), which generally had significantly lower CYP2C9 inhibition than 
the pyrazolopyrimidine series (CYP2C9 IC50 for 9 = 5.3 μM) without bringing other obvious 
liabilities into play[34]. Therefore, they were encouraged that switching to this scaffold may 
also be the best approach to try to increase the range of possible sites of metabolism, without 
greatly increasing clearance. Then APD597 (JNJ-38431055, Figure 5, 10) was then developed, 
which described the second generation trisubstituted pyrimidine agonists with improved 
solubility, pharmacokinetic and metabolism characteristics and excellent in vivo activity. In 
the anesthetized Guinea Pig, treatment with APD597 (hGPR119 EC50 = 46 nM) did not 
produce any dose-related, statistically significant effects on mean arterial blood pressure 
(MAP), heart rate (HR) or on the electrocardiogram (ECG) at cumulative doses up to 5 
mg/kg IV, when compared to vehicle controls. Preliminary safety studies in rat (14-day) and 
dog (7-day) revealed no obvious liabilities that would prevent further development[34]. In 
December 2008, Ortho-McNeil–Janssen Pharmaceuticals, Inc., put APD668 on hold to 
initiated phase 1 clinical trials of the second Arena-discovered GPR119 agonist, APD597 for 
the treatment of T2DM (Arena Pharmaceuticals, Inc., Press Release, December 15, 2008; 
http://arna.client.shareholder.com/releasedetail.cfm?ReleaseID=354391 ). 
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4.2.2. Astellas 
Compounds effective in stimulating insulin secretion and inhibiting the increase of blood 
sugar levels have been reported by Astellas. These were derived from a bicyclic scaffold 
in which a pyrimidine ring was fused to an aromatic (e.g., thiophene, thiazole, and 
pyridine) or a nonaromatic (e.g., dihydrothiophene, dihydrofuran, and cycloalkyls) 
heterocycle[8]. Detailed pharmacological data on two disclosed GPR119 agonists from 
Astellas have been presented. The first generation analog, AS1535907 (Figure 6, 11), 
increased intracellular cAMP levels in GPR119 transfected HEK293 cells (EC50 = 1.5 μM) 
and enhanced insulin secretion in the mouse NIT-1 pancreatic β-cell line and rat perfused 
pancreas. In vivo studies in normal and db/db mice suggested improved glucose tolerance 
following oral treatment with this compound (10 mg/kg). Gene expression studies also 
revealed that AS1535907 upregulated PC-1 mRNA, thus suggesting possible involvement 
in insulin biosynthesis[8, 35]. 
 
Figure 6. Compounds AS1535907 and AS1907417 from Astellas. 
Further SAR optimization resulted in the second generation compound, AS1907417 (hEC50 
= 1.1 μM, Figure 6, 12), which improved upon the metabolism and efficacy liabilities 
associated with AS1535907, AS1907417 effectively reduced glucose levels in normal and 
diabetic mice. Significant increases in insulin secretion, were observed in vitro at 
concentrations of 0.3μM and in vivo after oral administration at doses of 3 mg/kg. The 
potential long term pharmacological efficacy of AS1907417 for preserving pancreatic β-cell 
function and insulin production was suggested by the reduction of plasma TG and NEFA 
levels in several diabetic animal models[8, 36]. 
4.2.3. Biovitrum 
Biovitrum has several published patent applications identifying GPR119 agonists which 
differ in the nature of the central aromatic ring (compounds 13–15)[8, 32]. The central 
heterocyclic ring consisted of a pyridine[37], pyradazine[38], pyrimidine[39], or pyrazine[40] 
nucleus, which was connected to the piperidine ring via an optionally substituted amino 
methylene (e.g., Figure 7, 13) or an oxymethylene linker. Compounds 13, 14, and 15 (Figure 
7) were reported to have EC50 values of 22, 46, and 14 nM, respectively, in a human GPR119 
cAMP HTRF (homogenous timeresolved fluorescence) assay. 
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Figure 7. Compounds 13-15 from Biovitrum. 
4.2.4. Bristol-Myers squibb 
The first series of GPR119 agonists reported by Bristol–Myers Squibb featured a [6,5], [6,6], 
or [6,7] bicyclic central core[41, 42]. Representative examples containing pyrimidine-fused 
pyrrazole, triazole, and morpholine ring systems are shown in Figure 8. The second BMS 
series featured a pyridone central core that was N-substituted with the aryl motif and linked 
to the piperidine motif at the 4-position through an oxygen linker (Figure 8, 19, 20;); 
pyridazone analogs have also been claimed as GPR119 modulators[43, 44] 
 
Figure 8. Compounds 16-20 from Bristol-Myers Squibb. 
4.2.5. GlaxoSmithKline 
Replacement of Arena’s pyrazolopyrimidine ring system with a dihydropyrrolopyrimidine 
scaffold was shown to be successful by researchers at GlaxoSmithKline[45, 46]. The two 
initial filings, from July 2006, describe agonists that retain a 6,7-dihydro-5H-pyrrolo[2,3-
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d]pyrimidine core unit (Figure 9). The third patent application contains compounds with a 
benzene, pyridine, pyrazine or pyridazine central core (e.g., 23, 24). The prototypical 
compound 21 (Figure 9) demonstrated an EC50 of 40 nM in a CHO6CRE reporter assay. In 
an oGTT, 21 reduced the glucose AUC by 28% (30 mg/kg) and 38% (10 mg/kg), respectively, 
in mice and rats. In addition, hyperinsulinemic clamp experiments in normal rats showed 
that compound 21 enhances whole body insulin sensitivity[8]. In these filings, compounds 
are described as having therapeutic value for diabetes and associated conditions, 
particularly T2DM, obesity, glucose intolerance, insulin resistance, metabolic syndrome X, 
hyperlipidemia, hypercholesterolemia and atherosclerosis. 
In addition to the pyrrolopyrimidine scaffold, a series of GPR119 agonists based on 
monocyclic six-membered aryl and heteroaryl cores have also been reported by 
GlaxoSmithKline[47]. GSK1292263 (Phase 2, hGPR119 pEC50 = 6.9 nM, rat GPR119 pEC50 = 
6.7 nM ) augmented insulin secretion and decreased glucose AUC in rodent glucose 
tolerance tests; an increased incretin secretion (GLP-1 and GIP) was also observed[8]. The 
safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral 
doses of GSK-1292263 were evaluated in a completed randomized, placebo-controlled 
clinical trial in healthy volunteers (ClinicalTrials.gov Identifier NCT00783549). A total of 69 
subjects received single escalating doses of GSK-1292263 (10-400 mg) prior to administration 
of a 250mg dose given once daily for 2 and 5 days, which was also evaluated in combination 
with sitagliptin (100 mg). Treatment with GSK-1292263 at all doses was described as well 
tolerated, with the most common drug-related effects being mild headache, dizziness, 
hyperhidrosis, flushing and post-oGTT hypoglycemia. Coadministration with sitagliptin 
increased plasma active GLP-1 concentrations and lowered total GLP-1, GIP and PYY levels; 
no effects on gastric emptying were observed with GSK1292263. The data support further 
evaluation of GSK-1292263 for the treatment of T2DM[48]. 
 
Figure 9. Compounds 21-24 from GlaxoSmithKline. 
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4.2.6. Merck 
Merck has two published patent applications describing GPR119 agonists which retain a 
4,4’-bipiperidine scaffold (Figure 10; 25 and 26)[49, 50]. Compound 26 depicts one such 
example containing a 5-fluoro pyrimidine. Although the data for specific Merck analogs are 
not available, several compounds have been claimed to exhibit an EC50 < 10 nM in the 
cAMP homogeneous time-resolved fluorescence (HTRF) assay[8].  
In 2006, Schering–Plough filed several patents describing spiro-azetidine and spiro-
azetidinone derivatives, which are described as T-calcium channels blockers, GPR119 
receptor agonists and Niemann-Pick C1-like protein-1 antagonists, with utility for the 
treatment of pain, diabetes and disorders of metabolism (Figure 10, 27) [32, 51, 52]. 
Compound 28 was described as a modest GPR119 agonist (cAMP IC50 = 1922 nM); 
replacement of the amide functionality with a urea resulted in a potent T-type calcium 
channel blocker, 29 (IW hCav3.2 IC50 = 23nM). 
 
Figure 10. Compounds 25-29 from Merck. 
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More recent published patent filings from Schering describe selective GPR119 modulators 
comprised of a fused pyrimidinone core (compounds 30 and 31)[53]. The patent application 
pertaining to 30 discloses a series of 6-substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-
4(3H)-ones and the patent application associated with 31 describes a closely related chemical 
series of 7-substituted 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-ones[54]. Both of 
these series of GPR119 modulators, which were reported to exhibit EC50 values ranging 
from about 50 nM to about 14,000 nM, are described as being useful for treating or 
preventing obesity, diabetes, metabolic disease, cardiovascular disease or a disorder related 
to the activity of GPR119 in a patient[32]. 
4.2.7. Metabolex 
GPR119 agonists from Metabolex are based on a five-membered central heterocyclic core 
that is linked directly to the piperidine motif at its C4 position and to the aryl motif through 
an oxymethylene spacer[55-58] (Figure 11). Most examples in this application showed 
agonist activity at 10 μM in the fluorescence resonance energy transfer (FRET) assay 
corresponding to increased intracellular cAMP levels. Glucose stimulated insulin secretion 
experiments using isolated rat islets are described and compound 32 showed 1.78-fold 
stimulation of insulin secretion at 16 mM glucose. oGTTs in mice are described and both 
compounds 32 and 33 significantly reduce glucose AUC[8]. 
 
Figure 11. Compounds 32 and 33 from Metabolex. 
Metabolex advanced their orally available GPR119 agonist MBX-2982 (Figure 4, 5) into clinical 
trials of T2D (Phase 2, completed)[59, 60]; rights to this compound were recently acquired by 
Sanofi-aventis. In preclinical studies, MBX-2982 was shown to increase cAMP levels in CHO 
cells expressing human GPR119 (EC50 = 3.9 nM) and to stimulate GSIS from isolated islets. 
Metabolex has recently completed two additional Phase 1 studies of MBX-2982 in subjects with 
pre-diabetes. In both studies, subjects with either impaired fasting glucose or impaired glucose 
tolerance were enrolled. The first study investigated the effect of four consecutive once daily 
doses (100 or 300 mg) of MBX-2982 on the pharmacokinetics of the drug as well as its effect on 
glucose excursions following a mixed meal (Metabolex, Inc., Press Release, November 12, 2008 
http://www.metabolex.com/news/nov122008.html ). In addition, the effect of MBX-2982 on 
insulin secretion during a graded glucose infusion was examined. MBX-2982 was rapidly 
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absorbed and its exposure at both doses approximately doubled on day four compared to day 
one, consistent with a terminal half-life of ~18 hr and supporting once daily dosing. The 
glucose excursions (area under the curve) following a mixed meal were reduced relative to 
baseline by 26% and 37%, respectively, for the 100 and 300 mg cohorts. During the graded 
glucose infusions, the exposure to glucose was reduced relative to baseline by 11% and 18% 
for the 100 and 300 mg cohorts, respectively. This was attributable to increases in insulin 
secretion. These results were all statistically significant. The second study in a pre-diabetic 
population was a five-day placebo-controlled multiple ascending dose study with an alternate 
formulation of MBX-2982 at doses of 25, 100, 300 and 600 mg (Metabolex, Inc., Press Release, 
October 13, 2009; http://www.metabolex.com/news/oct132009.html ). Once daily dosing 
provided markedly enhanced exposures and improved dose proportionality, giving sustained 
levels of MBX-2982 predicted to be maximally effective. The effect of each dose on the glucose 
excursions following a mixed meal and an oral glucose challenge was investigated. All four 
doses of MBX-2982 produced statistically significant decreases in the glucose excursion 
following a mixed meal ranging from 34% to 51%. Similar decreases were also observed 
following the glucose challenge. In both studies, MBX-2982 was safe and generally well 
tolerated with no serious adverse events, adverse event trends or dose-limiting toxicities. 
These results provide continued clinical validation of the potential therapeutic benefits of 
MBX-2982 in the treatment of type 2 diabetes. Phase 2 trials for MBX-2982 has been completed 
in evaluating its efficacy, safety, tolerability, and pharmacokinetics following daily 
administration for 4 weeks in patients with T2D. 
4.2.8. Novartis/IRM 
Genomics Institute of the Research Foundation (GNF) has disclosed an extensive set of 
GPR119 agonists containing a heterocyclic sulfonamide as a novel left-side structural 
motif[61-63]. Compounds of this patent application are defined in part by the terminal 
tetrahydroisoquinoline depicted in 34 (Figure 12)in February 2007. Compound 35 is 
representative of IRM’s second chemical series of GPR119 modulators which was filed later 
in 2007[32, 64]. These compounds were reported to be similarly potent in stimulating cAMP 
in Flp-In-CHO-hGPR119 cells, and are purported to be useful for the treatment or 
prevention of disorders associated with this receptor. 
 
Figure 12. Compounds 34 and 35 from Novartis/IRM. 
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4.2.9. Prosidion Ltd. 
The GPR119 agonist program at Prosidion evolved from their earlier lead PSN632408 
(Figure 13, EC50 = 5.6 μM, Emax = 110%). Replacement of the left-side pyridine ring with 
the more commonly employed methanesulfonyl phenyl motif (Figure 13), while retaining 
the oxadiazole core, was shown to be tolerated (e.g., 37: EC50 = 3.8 μM, Emax = 243%)[8, 
65]. Refer to Arena analogs, introducing a fluoro substituent meta to the sulfone, moving 
the fluoro group adjacent to the sulfone moiety, as well as incorporating an (R)-methyl 
group to the methyleneoxy linker provided a more potent analog, PSN119-2 (EC50 = 0.4 
μM, Emax = 358%), a potent GPR119 agonist that stimulated insulin secretion from HIT-T15 
cells (EC50 = 18 nM) and GLP-1 release from GLUTag cells (EC50 = 8 nM)[65]. In rats, this 
compound improved oral glucose tolerance (10, 30 mg/kg, p.o.), delayed gastric 
emptying, and reduced food intake, thus supporting the premise that PSN119-2 as a 
GPR119 agonist could be effective oral antidiabetic agents that have the added potential to 
cause weight loss[8]. 
 
Figure 13. Compounds 36-41 from Prosidion Ltd. 
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Applications were filed in 2007 disclosed GPR119 agonists by Prosidion containing a central 
acyclic alkoxylene or alkylene spacer instead of the oxadiazole core. Compound 39 was the 
initial hit[66] (Figure 13), which demonstrated good potency (EC50 = 0.5 μM) but poor 
efficacy (Emax = 33%). replacing the pyridine ring with the 3-fluoro-4-methanesulfoxide 
phenyl moiety provided analogs with superior potency and efficacy (e.g., PSN119-1, EC50 = 
0.5 μM, Emax = 407%). In several rodent models of obesity and type 2 diabetes, PSN119-1 
reduced food intake and improved oral glucose tolerance, giving credence to the premise 
that GPR119 agonists have the makings of effective oral antidiabesic agents. When 
administered orally to rats, this compound achieved high plasma concentrations, as did its 
active sulfone metabolite PSN119-1M (EC50 = 0.2 μM, Emax = 392%)[67] (Figure 13).  
More recently, the Prosidion group described GPR119 agonists in which the potentially 
labile tert-butylcarbamate functionality was replaced with bioisosteric heteroaryl groups, in 
particular with an oxadiazole similar to Arena’s AR231453. Several azetidine-based GPR119 
agonists (Figure 14) have also been disclosed by Prosidion [8, 68, 69]. These analogs featured 
an appropriately substituted biaryl moiety five-membered heterocycle connected to the 
azetidine through an oxygen atom (e.g., 42, 43). Preferred analogs within these inventions 
were claimed to exhibit an EC50 of less than 1 μM (HIT-T15 Camp and insulin secretion 
assays), to statistically reduce glucose excursion in rat oGTTs (≤ 10 mg/kg, p.o.), as well as to 
demonstrate a statistically significant hypophagic effect at a dose of ≤ 100 mg/kg. 
Optimization of the above described chemical series resulted in identification of the clinical 
candidate PSN821[8], the structure of which has not been disclosed. In pre-clinical studies, 
PSN821 has demonstrated pronounced glucose lowering in rodent models of type 2 diabetes 
with no loss of efficacy on repeated administration, and substantial reductions of body 
weight in rodent models of obesity. In male diabetic ZDF rats, both acute and chronic oral 
administration of PSN821, significantly and dose-dependently reduced glucose excursions 
in an oral glucose tolerance test. In prediabetic male ZDF rats, weeks significantly lowered 
nonfasting blood glucose concentrations and HbA1c levels compared to vehicle. 
Furthermore, in weight-stable, dietary-induced obese (DIO) female Wistar rats, daily oral 
dosing of PSN821 for 4 weeks reduced body weight substantially and significantly by 8.8%, 
approaching the 10.6% weight loss induced by a high dose of the prescribed anti-obesity 
agent sibutramine[70].  
In the double-blind, placebo-controlled, ascending single dose first-in-human study, PSN821 
was generally well tolerated at doses up to 3000mg in healthy volunteers and 1000mg (the 
top dose tested) in patients with type 2 diabetes, with no clinically important adverse effects 
on laboratory tests, 12-lead ECGs or vital signs. Pharmacokinetics showed a profile 
consistent with once or twice daily dosing. In patients with type 2 diabetes, PSN821 showed 
substantial and statistically significant reductions in glucose responses to a standard 
nutrient challenge of approximately 30% at 250mg and 500mg. The data from this study was 
supportive of progression of PSN821 into a 14-day dosing ascending multiple dose study in 
healthy subjects and patients with type 2 diabetes and will be submitted for presentation at 
a scientific meeting together with the data from the multiple ascending dose study. 
 
GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment 75 
 
Figure 14. Compounds 42-45 from Prosidion Ltd. 
The discovery team at Prosidion has explored a unique approach of combining DPP-4 
inhibition and GPR119 agonism in a single molecule[71]. Introduction of the 
cyanopyrrolidine pharmacophore of known DPP-4 inhibitors on the aryl motif of their 
GPR119 agonists provided compounds, which displayed dual activity as agonists of GPR119 
and inhibitors of DPP-IV (Figure 14, 44 and 45). Limited biological data are available from 
this SAR effort. PSN-IV/119-1 (structure not disclosed) was recently reported to exhibit a 
GPR119 EC50 of 2.24mmol/L and DPP-4 IC50 of 0.2mmol/L[72]. Oral administration of PSN-
IV/119-1 at a dose of 30mg/kg in diabetic ZDF rats led to a greater reduction in glucose AUC 
compared to the DPP-IV inhibitor sitagliptin (58% vs. 22%); at a lower dose of 10 mg/kg, the 
activity was comparable to sitagliptin (20 mg/kg).  
4.3. The pharmacophore model for potent GPR119 agonists 
Xiaoyun Zhu et al. have generated pharmacophore models using Discovery Studio V2.1 for 
a diverse set of molecules as GPR119 agonist with an aim to obtain the pharmacophore 
model that would provide a hypothetical picture of the chemical features responsible for 
activity[73]. The best hypothesis (Figure 15) consisting of five features, namely, two 
hydrogen bond acceptors and three hydrophobic features, has a correlation coefficient of 
0.969, cost difference of 62.68, RMS of 0.653, and configuration cost of 15.24, suggesting that 
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a highly predictive pharmacophore model was successfully obtained. The Fit-Value and 
Estimate activity of GSK-1292263, which have completed phase II clinical trials as a GPR119 
agonist (Figure 15), based on Hypo1 in Decoy set are 8.8 and 7.7 (nM), respectively. The 
validated pharmacophore generated can be used to evaluate how well any newly designed 
compound maps on the pharmacophore before undertaking any further study including 
synthesis, and also used as a three-dimensional query in database searches to identify 
compounds with diverse structures that can potentially agonist GPR119[73].  
 
Figure 15. The first pharmacophore model for potent G protein-coupled receptor 119 agonist[73]. A: 
The best pharmacophore model Hypo1 where H and HBA are illustrated in cyan and green, 
respectively. B: Best pharmacophore model Hypo1 aligned to GSK1292263. 
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5. Future directions and concluding remarks 
In summary, GPR119 agonists seem to provide a completely novel and previously 
unexplored approach to incretin therapy in patients with T2DM, increasing glucose-
dependent insulin secretion through two complementary mechanisms: directly, through 
actions on the β cell, and indirectly, through enhancement of GLP-1 and GIP release from 
the GI tract. It is also worth pointing out the obvious potential advantages that could 
theoretically be obtained by the co-administration of a GPR119 agonist (with a 
mechanism as a GLP-1 secretagogue) and a DPP-4 inhibitor (with a mechanism to protect 
secreted GLP-1), and some preliminary and recent published data support this attractive 
concept. Such a strategy may not only provide improved glycemic control, but also 
induce weight loss, a feature observed with GLP-1 mimetics but not with DPP-4 
inhibitors. Following the recent entry of the GPR119 agonists MBX-2982, GSK-1292263 
and PSN821 into clinical development, the value of these compounds as a new class of 
therapeutics for type 2 diabetes and associated obesity is likely to be determined within 
the next few years. 
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